;PMID: 8161790
;source_file_1231.mrg
;Release 0.9 of PennBioIE
;Funded by NSF ITR EIA-0205448

;0)section:[e:0..32] = [t:0..32]
;1)sentence:[e:37..106] = [t:37..106]
;2)section:[e:110..176] = [t:110..176]
;3)section:[e:180..263] = [t:180..263]
;4)sentence:[e:267..487] = [t:267..487]
;5)sentence:[e:488..667] = [t:488..667]
;6)sentence:[e:669..894] = [t:669..894]
;7)sentence:[e:896..1024] = [t:896..1024]
;8)sentence:[e:1025..1174] = [t:1025..1174]
;9)sentence:[e:1175..1335] = [t:1175..1335]
;10)sentence:[e:1336..1514] = [t:1336..1514]
;11)section:[e:1518..1562] = [t:1518..1562]

;section 0 Span:0..32
;Blood  1994 Apr 15;83(8):2248-54
(SEC
  (FRAG (NNP:[0..5] Blood) (CD:[7..11] 1994) (NNP:[12..15] Apr) (CD:[16..18] 15)
        (CC:[18..22] ;83-LRB-) (CD:[22..23] 8) (-RRB-:[23..24] -RRB-)
        (CD:[24..29] :2248) (::[29..30] -) (CD:[30..32] 54)))

;sentence 1 Span:37..106
;Mutations of the N-ras gene in juvenile chronic myelogenous leukemia.
;[54..59]:gene-rna:"N-ras"
;[68..105]:malignancy:"juvenile chronic myelogenous leukemia"
(SENT
  (NP-HLN
    (NP (NNS:[37..46] Mutations))
    (PP (IN:[47..49] of)
      (NP (DT:[50..53] the) (NN:[54..59] N-ras) (NN:[60..64] gene)))
    (PP (IN:[65..67] in)
      (NP (JJ:[68..76] juvenile) (JJ:[77..84] chronic) (JJ:[85..96] myelogenous)
          (NN:[97..105] leukemia)))
    (.:[105..106] .)))

;section 2 Span:110..176
;Miyauchi J, Asada M, Sasaki M, Tsunematsu Y, Kojima S, Mizutani S.
(SEC
  (FRAG (NNP:[110..118] Miyauchi) (NNP:[119..121] J,) (NNP:[122..127] Asada)
        (NNP:[128..130] M,) (NNP:[131..137] Sasaki) (NNP:[138..140] M,)
        (NNP:[141..151] Tsunematsu) (NNP:[152..153] Y) (,:[153..154] ,)
        (NNP:[155..161] Kojima) (NNP:[162..164] S,) (NNP:[165..173] Mizutani)
        (NNP:[174..176] S.)))

;section 3 Span:180..263
;Department of Virology, National Children's Medical Research Center, Tokyo, 
;Japan.
(SEC
  (FRAG (NNP:[180..190] Department) (IN:[191..193] of) (NNP:[194..202] Virology)
        (,:[202..203] ,) (NNP:[204..212] National) (NNP:[213..221] Children)
        (POS:[221..223] 's) (NNP:[224..231] Medical) (NNP:[232..240] Research)
        (NNP:[241..247] Center) (,:[247..248] ,) (NNP:[249..254] Tokyo)
        (,:[254..255] ,) (NNP:[257..262] Japan) (.:[262..263] .)))

;sentence 4 Span:267..487
;Juvenile chronic myelogenous leukemia (JCML), a myeloproliferative disorder
;of  childhood, is distinct from adult-type chronic myelogenous leukemia (CML)
;and  bears resemblance to chronic myelomonocytic leukemia (CMMoL).
;[267..304]:malignancy:"Juvenile chronic myelogenous leukemia"
;[306..310]:malignancy:"JCML"
;[375..414]:malignancy:"adult-type chronic myelogenous leukemia"
;[416..419]:malignancy:"CML"
;[447..478]:malignancy:"chronic myelomonocytic leukemia"
;[480..485]:malignancy:"CMMoL"
(SENT
  (S
    (NP-SBJ
      (NP
        (NP (JJ:[267..275] Juvenile) (JJ:[276..283] chronic)
            (JJ:[284..295] myelogenous) (NN:[296..304] leukemia))
        (NP (-LRB-:[305..306] -LRB-) (NN:[306..310] JCML)
            (-RRB-:[310..311] -RRB-)))
      (,:[311..312] ,)
      (NP
        (NP (DT:[313..314] a) (JJ:[315..333] myeloproliferative)
            (NN:[334..342] disorder))
        (PP (IN:[343..345] of)
          (NP (NN:[347..356] childhood)))))
    (,:[356..357] ,)
    (VP
      (VP (VBZ:[358..360] is)
        (ADJP-PRD (JJ:[361..369] distinct)
          (PP (IN:[370..374] from)
            (NP
              (NML (JJ:[375..380] adult) (HYPH:[380..381] -)
                   (NN:[381..385] type))
              (NML
                (NML (JJ:[386..393] chronic) (JJ:[394..405] myelogenous)
                     (NN:[406..414] leukemia))
                (NML (-LRB-:[415..416] -LRB-) (NN:[416..419] CML)
                     (-RRB-:[419..420] -RRB-)))))))
      (CC:[421..424] and)
      (VP (VBZ:[426..431] bears)
        (NP
          (NP (NN:[432..443] resemblance))
          (PP (TO:[444..446] to)
            (NP
              (NP (JJ:[447..454] chronic) (JJ:[455..469] myelomonocytic)
                  (NN:[470..478] leukemia))
              (NP (-LRB-:[479..480] -LRB-) (NN:[480..485] CMMoL)
                  (-RRB-:[485..486] -RRB-)))))))
    (.:[486..487] .)))

;sentence 5 Span:488..667
;Since mutations in  the N-ras gene have been found at high frequencies in
;CMMoL, but only rarely in  CML, we analyzed mutations activating the N-ras
;gene in 20 patients with JCML.
;[512..517]:gene-rna:"N-ras"
;[562..567]:malignancy:"CMMoL"
;[589..592]:malignancy:"CML"
;[631..636]:gene-rna:"N-ras"
;[662..666]:malignancy:"JCML"
(SENT
  (S
    (SBAR-ADV (IN:[488..493] Since)
      (S
        (NP-SBJ-3
          (NP (NNS:[494..503] mutations))
          (PP (IN:[504..506] in)
            (NP (DT:[508..511] the) (NN:[512..517] N-ras) (NN:[518..522] gene))))
        (VP (VBP:[523..527] have)
          (VP (VBN:[528..532] been)
            (VP
              (VP (VBN:[533..538] found)
                (NP-3 (-NONE-:[538..538] *))
                (PP=2 (IN:[539..541] at)
                  (NP (JJ:[542..546] high) (NNS:[547..558] frequencies)))
                (PP=1 (IN:[559..561] in)
                  (NP (NN:[562..567] CMMoL))))
              (,:[567..568] ,) (CC:[569..572] but)
              (VP
                (ADVP (RB:[573..577] only) (RB:[578..584] rarely))
                (PP=2 (-NONE-:[584..584] *NOT*))
                (PP=1 (IN:[585..587] in)
                  (NP (NN:[589..592] CML)))))))))
    (,:[592..593] ,)
    (NP-SBJ (PRP:[594..596] we))
    (VP (VBD:[597..605] analyzed)
      (NP
        (NP (NNS:[606..615] mutations))
        (VP (VBG:[616..626] activating)
          (NP (DT:[627..630] the) (NN:[631..636] N-ras) (NN:[637..641] gene))))
      (PP (IN:[642..644] in)
        (NP
          (NP (CD:[645..647] 20) (NNS:[648..656] patients))
          (PP (IN:[657..661] with)
            (NP (NN:[662..666] JCML))))))
    (.:[666..667] .)))

;sentence 6 Span:669..894
;We used the strategy for analysis of gene mutations based on in vitro DNA 
;amplification by polymerase chain reaction (PCR) followed by single-strand 
;conformation polymorphism (SSCP) analysis and/or direct sequence analysis.
;[761..771]:gene-protein:"polymerase"
(SENT
  (S
    (NP-SBJ (PRP:[669..671] We))
    (VP (VBD:[672..676] used)
      (NP
        (NP
          (NP (DT:[677..680] the) (NN:[681..689] strategy))
          (PP (IN:[690..693] for)
            (NP
              (NP (NN:[694..702] analysis))
              (PP (IN:[703..705] of)
                (NP (NN:[706..710] gene) (NNS:[711..720] mutations))))))
        (VP (VBN:[721..726] based)
          (NP (-NONE-:[726..726] *))
          (PP (IN:[727..729] on)
            (NP
              (NP
                (NP
                  (NML (FW:[730..732] in) (FW:[733..738] vitro))
                  (NN:[739..742] DNA) (NN:[744..757] amplification))
                (PP (IN:[758..760] by)
                  (NP
                    (NP (NN:[761..771] polymerase) (NN:[772..777] chain)
                        (NN:[778..786] reaction))
                    (NP (-LRB-:[787..788] -LRB-) (NN:[788..791] PCR)
                        (-RRB-:[791..792] -RRB-)))))
              (VP (VBN:[793..801] followed)
                (NP (-NONE-:[801..801] *))
                (PP-LGS (IN:[802..804] by)
                  (NP
                    (NP
                      (NML
                        (NML
                          (NML (JJ:[805..811] single) (HYPH:[811..812] -)
                               (NN:[812..818] strand))
                          (NN:[820..832] conformation)
                           (NN:[833..845] polymorphism))
                        (NML (-LRB-:[846..847] -LRB-) (NN:[847..851] SSCP)
                             (-RRB-:[851..852] -RRB-)))
                      (NN:[853..861] analysis))
                    (CC:[862..868] and/or)
                    (NP (JJ:[869..875] direct) (NN:[876..884] sequence)
                        (NN:[885..893] analysis))))))))))
    (.:[893..894] .)))

;sentence 7 Span:896..1024
;Nucleotide sequence analysis showed single nucleotide substitutions involving
; codons 12, 13, or 61 in six of 20 patients (30%).
;[932..963]:variation-type:"single nucleotide substitutions"
;[975..981]...[982..984]...[986..988]...[993..995]:variation-location:"codons"
;..."12"..."13"..."61"
(SENT
  (S
    (NP-SBJ (NN:[896..906] Nucleotide) (NN:[907..915] sequence)
            (NN:[916..924] analysis))
    (VP (VBD:[925..931] showed)
      (NP
        (NP (JJ:[932..938] single) (NN:[939..949] nucleotide)
            (NNS:[950..963] substitutions))
        (VP (VBG:[964..973] involving)
          (NP
            (NP
              (NML-1 (NNS:[975..981] codons))
              (CD:[982..984] 12))
            (,:[984..985] ,)
            (NP
              (NML-1 (-NONE-:[985..985] *P*))
              (CD:[986..988] 13))
            (,:[988..989] ,) (CC:[990..992] or)
            (NP
              (NML-1 (-NONE-:[992..992] *P*))
              (CD:[993..995] 61)))))
      (PP-LOC (IN:[996..998] in)
        (NP
          (NP (CD:[999..1002] six))
          (PP (IN:[1003..1005] of)
            (NP (CD:[1006..1008] 20) (NNS:[1009..1017] patients)))
          (PRN (-LRB-:[1018..1019] -LRB-)
            (NP (CD:[1019..1021] 30) (NN:[1021..1022] %))
            (-RRB-:[1022..1023] -RRB-)))))
    (.:[1023..1024] .)))

;sentence 8 Span:1025..1174
;Four of six patients with  mutations were in chronic phase and the other two
;in blast crisis, indicating no  apparent correlation with disease stage.
;[1052..1061]:variation-event:"mutations"
;[1070..1083]:malignancy:"chronic phase"
;[1105..1117]:malignancy:"blast crisis"
(SENT
  (S
    (S
      (NP-SBJ=2
        (NP (CD:[1025..1029] Four))
        (PP (IN:[1030..1032] of)
          (NP
            (NP (CD:[1033..1036] six) (NNS:[1037..1045] patients))
            (PP (IN:[1046..1050] with)
              (NP (NNS:[1052..1061] mutations))))))
      (VP (VBD:[1062..1066] were)
        (PP-PRD=1 (IN:[1067..1069] in)
          (NP (JJ:[1070..1077] chronic) (NN:[1078..1083] phase)))))
    (CC:[1084..1087] and)
    (S
      (NP-SBJ=2 (DT:[1088..1091] the) (JJ:[1092..1097] other)
                (CD:[1098..1101] two))
      (VP
        (PP-PRD=1 (IN:[1102..1104] in)
          (NP (NN:[1105..1110] blast) (NN:[1111..1117] crisis)))
        (,:[1117..1118] ,)
        (S-ADV
          (NP-SBJ (-NONE-:[1118..1118] *))
          (VP (VBG:[1119..1129] indicating)
            (NP
              (NP (DT:[1130..1132] no) (JJ:[1134..1142] apparent)
                  (NN:[1143..1154] correlation))
              (PP (IN:[1155..1159] with)
                (NP (NN:[1160..1167] disease) (NN:[1168..1173] stage))))))))
    (.:[1173..1174] .)))

;sentence 9 Span:1175..1335
;Most of the patients with mutations  were in the older age group with poor
;prognosis, although one patient in the  younger age group also harbored the
;mutation.
;[1201..1210]:variation-event:"mutations"
;[1326..1334]:variation-event:"mutation"
(SENT
  (S
    (NP-SBJ
      (NP (JJS:[1175..1179] Most))
      (PP (IN:[1180..1182] of)
        (NP
          (NP (DT:[1183..1186] the) (NNS:[1187..1195] patients))
          (PP (IN:[1196..1200] with)
            (NP (NNS:[1201..1210] mutations))))))
    (VP (VBD:[1212..1216] were)
      (PP-PRD (IN:[1217..1219] in)
        (NP
          (NP (DT:[1220..1223] the) (JJR:[1224..1229] older)
              (NN:[1230..1233] age) (NN:[1234..1239] group))
          (PP (IN:[1240..1244] with)
            (NP (JJ:[1245..1249] poor) (NN:[1250..1259] prognosis)))))
      (,:[1259..1260] ,)
      (SBAR (IN:[1261..1269] although)
        (S
          (NP-SBJ
            (NP (CD:[1270..1273] one) (NN:[1274..1281] patient))
            (PP (IN:[1282..1284] in)
              (NP (DT:[1285..1288] the) (JJR:[1290..1297] younger)
                  (NN:[1298..1301] age) (NN:[1302..1307] group))))
          (ADVP (RB:[1308..1312] also))
          (VP (VBD:[1313..1321] harbored)
            (NP (DT:[1322..1325] the) (NN:[1326..1334] mutation))))))
    (.:[1334..1335] .)))

;sentence 10 Span:1336..1514
;These data suggest that N-ras gene  mutations may be involved in the
;pathogenesis and/or prognosis of JCML and  provide further evidence that JCML
;is an entity distinct from CML.
;[1360..1365]:gene-rna:"N-ras"
;[1438..1442]:malignancy:"JCML"
;[1478..1482]:malignancy:"JCML"
;[1510..1513]:malignancy:"CML"
(SENT
  (S
    (NP-SBJ (DT:[1336..1341] These) (NNS:[1342..1346] data))
    (VP
      (VP (VBP:[1347..1354] suggest)
        (SBAR (IN:[1355..1359] that)
          (S
            (NP-SBJ-1 (NN:[1360..1365] N-ras) (NN:[1366..1370] gene)
                      (NNS:[1372..1381] mutations))
            (VP (MD:[1382..1385] may)
              (VP (VB:[1386..1388] be)
                (VP (VBN:[1389..1397] involved)
                  (NP-1 (-NONE-:[1397..1397] *))
                  (PP-CLR (IN:[1398..1400] in)
                    (NP
                      (NP (DT:[1401..1404] the) (NN:[1405..1417] pathogenesis)
                          (CC:[1418..1424] and/or) (NN:[1425..1434] prognosis))
                      (PP (IN:[1435..1437] of)
                        (NP (NN:[1438..1442] JCML)))))))))))
      (CC:[1443..1446] and)
      (VP (VBP:[1448..1455] provide)
        (NP (JJ:[1456..1463] further) (NN:[1464..1472] evidence)
          (SBAR (IN:[1473..1477] that)
            (S
              (NP-SBJ (NN:[1478..1482] JCML))
              (VP (VBZ:[1483..1485] is)
                (NP-PRD
                  (NP (DT:[1486..1488] an) (NN:[1489..1495] entity))
                  (ADJP (JJ:[1496..1504] distinct)
                    (PP (IN:[1505..1509] from)
                      (NP (NN:[1510..1513] CML)))))))))))
    (.:[1513..1514] .)))

;section 11 Span:1518..1562
;PMID: 8161790 [PubMed - indexed for MEDLINE]
(SEC
  (FRAG (NNP:[1518..1522] PMID) (::[1522..1523] :) (CD:[1524..1531] 8161790)
        (NN:[1532..1533] -LSB-) (NNP:[1533..1539] PubMed) (::[1540..1541] -)
        (NN:[1542..1549] indexed) (IN:[1550..1553] for)
        (NNP:[1554..1562] MEDLINE-RSB-)))
